An open-label, multi-center trial to evaluate the feasibility and safety of short-term treatment with subcutaneously injected certoparin (8000 U anti-Xa twice daily) in patients with persistent nonvalvular atrial fibrillation.

Trial Profile

An open-label, multi-center trial to evaluate the feasibility and safety of short-term treatment with subcutaneously injected certoparin (8000 U anti-Xa twice daily) in patients with persistent nonvalvular atrial fibrillation.

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Certoparin sodium (Primary)
  • Indications Atrial fibrillation
  • Focus Adverse reactions
  • Acronyms AFFECT
  • Most Recent Events

    • 28 Feb 2017 Last checked against ClinicalTrials.gov record.
    • 31 Aug 2010 Actual end date (August 2006) added as reported by ClinicalTrials.gov.
    • 21 Mar 2008 Status changed from in progress to completed as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top